Sepsis syndrome and associated sequelae in patients at high risk for gram-negative sepsis
| Autor: | K, Conboy, L S, Welage, C A, Walawander, L C, Duffy, R C, Welliver, M A, Zielezny, J T, DiPiro, M A, Raebel, T H, Grasela |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Aged 80 and over Male Cross Infection Adolescent Incidence Bacteremia Middle Aged Systemic Inflammatory Response Syndrome United States Anti-Bacterial Agents Community-Acquired Infections Hospitalization Risk Factors Population Surveillance Urinary Tract Infections Humans Female Prospective Studies Gram-Negative Bacterial Infections Respiratory Tract Infections Aged |
| Zdroj: | Pharmacotherapy. 15(1) |
| ISSN: | 0277-0008 |
| Popis: | We conducted a prospective surveillance study of 80 hospitals across the United States to determine the incidence of sepsis syndrome and its associated sequelae in hospitalized patients over age 18 years who were administered antibiotics for suspected or documented gram-negative infection. A sample of 1754 hospitalized patients were followed from onset of antimicrobial therapy to discharge or death. Mortality rates (MR) varied depending on the suspected source of sepsis syndrome. For patients in whom the syndrome was associated with community-acquired urinary tract infections, mortality was 20% (relative risk [RR] = 0.51, p0.05), for those with trauma 20.6% (RR = 0.51, p0.05), and patients with nosocomial respiratory tract infections 57.1% (RR = 1.66, p0.05). More than two complications occurred in 65.2% of patients under age 60 years (MR 31%), 40.8% of those age 60-80 (MR 42%), and 35.6% of patients older than 80 years (MR 33.3%, p0.05). Various patient populations had significant differences in both the incidence of the syndrome and its complications, and consequent mortality. Perhaps morbidity as well as mortality should be used as outcomes when testing the efficacy of innovative therapies for sepsis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text